Biocept, Inc. (BIOC) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.08 k

Shareholding (Dec 2023)

FII

0.13%

Held by 3 FIIs

DII

98.55%

Held by 1 DIIs

Promoter

0.00%

Who are in the management team of Biocept, Inc.?

22-Jun-2025

As of March 2022, the management team of Biocept, Inc. includes Non-Executive Chairman David Hale, President and CEO Michael Nall, Directors Samuel Riccitelli, Marsha Chandler, Bruce Gerhardt, and Ivor Royston. They oversee the company's strategic direction and operations.

Is Biocept, Inc. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is insufficient technical data for Biocept, Inc. to determine a bullish or bearish outlook.

Is Biocept, Inc. overvalued or undervalued?

25-Jun-2025

As of October 15, 2023, Biocept, Inc. is considered overvalued due to its high price-to-earnings ratio of 45.2, a price-to-book ratio of 6.8, and a low return on equity of 2.3%, which are not justified by its financial performance compared to industry peers.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 0 Million ()

P/E

Industry P/E

Dividend Yield

0.00%

Debt Equity

-4.73

Return on Equity

-2,859.40%

Price to Book

0.00

Revenue and Profits:

Net Sales:

1 Million

(Quarterly Results - Jun 2023)

Net Profit:

-4 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

0.0%

6 Months

0.0%

1 Year

0.0%

2 Years

-99.8%

3 Years

-99.99%

4 Years

-100.0%

5 Years

-100.0%

Biocept, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

25.18%

EBIT Growth (5y)

-5.21%

EBIT to Interest (avg)

-18.23

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-4.73

Sales to Capital Employed (avg)

2.73

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

11.84%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.00

EV to EBIT

0.17

EV to EBITDA

0.18

EV to Capital Employed

1.07

EV to Sales

-0.37

PEG Ratio

Dividend Yield

ROCE (Latest)

641.56%

ROE (Latest)

-2859.40%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bullish

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2023

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 7 Schemes (1.32%)

Foreign Institutions

Held by 3 Foreign Institutions (0.13%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'23 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2023 is -14.29% vs -30.00% in Mar 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2023 is 49.30% vs 29.70% in Mar 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'23",
        "Mar'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.60",
          "val2": "0.70",
          "chgp": "-14.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.40",
          "val2": "-6.50",
          "chgp": "16.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "2.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.60",
          "val2": "-7.10",
          "chgp": "49.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-10,380.30%",
          "val2": "-10,546.80%",
          "chgp": "16.65%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is -57.68% vs 122.55% in Dec 2021",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is -1,046.43% vs 84.27% in Dec 2021",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "25.90",
          "val2": "61.20",
          "chgp": "-57.68%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-29.80",
          "val2": "0.20",
          "chgp": "-15,000.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-32.10",
          "val2": "-2.80",
          "chgp": "-1,046.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,236.90%",
          "val2": "-39.30%",
          "chgp": "-119.76%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'23 - QoQ

Jun'23

Mar'23

Change(%)

Net Sales

0.60

0.70

-14.29%

Operating Profit (PBDIT) excl Other Income

-5.40

-6.50

16.92%

Interest

0.10

0.00

Exceptional Items

2.40

0.00

Consolidate Net Profit

-3.60

-7.10

49.30%

Operating Profit Margin (Excl OI)

-10,380.30%

-10,546.80%

16.65%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2023 is -14.29% vs -30.00% in Mar 2023

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2023 is 49.30% vs 29.70% in Mar 2023

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'22

Dec'22

Dec'21

Change(%)

Net Sales

25.90

61.20

-57.68%

Operating Profit (PBDIT) excl Other Income

-29.80

0.20

-15,000.00%

Interest

0.30

Exceptional Items

0.00

Consolidate Net Profit

-32.10

-2.80

-1,046.43%

Operating Profit Margin (Excl OI)

-1,236.90%

-39.30%

-119.76%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2022 is -57.68% vs 122.55% in Dec 2021

Consolidated Net Profit

YoY Growth in year ended Dec 2022 is -1,046.43% vs 84.27% in Dec 2021

All Annual Results

Company CV

About Biocept, Inc.

Biocept, Inc.

Pharmaceuticals & Biotechnology

Biocept, Inc. is a molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

Company Coordinates

Company Details

5810 Nancy Ridge Dr , SAN DIEGO CA : 92121-2834

Tel: 1 858 3208200

https://biocept.com/

Registrar Details

Biocept, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

Who are in the management team of Biocept, Inc.?

Watch in Real-Time

Is Biocept, Inc. technically bullish or bearish?

Is Biocept, Inc. overvalued or undervalued?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Dec 2023

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'23 - QoQ

Annual Results Snapshot (Consolidated) - Dec'22

About Biocept, Inc.

Company Coordinates